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ABSTRACT  
In the past 12 months, many important new clinical trials in cardiology have had their first 
conference presentation and publication. This paper presents a constructive critical appraisal 
of 6 key studies. In time order of first presentation they are CABANA, ATTR-ACT, COAPT, 
DECLARE, REDUCE-IT, and AUGUSTUS. For each study, our aim is to document and 
interpret the main findings, paying attention to new findings, their research context, and study 
limitations. These topical examples also provide methodological insights pertinent to future 
clinical trials research. 
 
CONDENSED ABSTRACT 
In the past 12 months, many important new clinical trials in cardiology have had their first 
conference presentation and publication. This paper presents a constructive critical appraisal 
of 6 key studies. For each study, our aim is to document and interpret the main findings, 
paying attention to new findings, their research context, and study limitations. These topical 
examples also provide methodological insights pertinent to future clinical trials research. 
 
Key words: Clinical Trials, Intention to Treat Analysis, Patient Selection, Statistics, 
Treatment Outcome  
 
Abbreviations and Acronyms 
CI = confidence interval 
CRNM = clinically relevant nonmajor  
CV = cardiovascular 
CVH = cardiovascular-related hospitalizations 
EPA = eicosapenteic acid 
HFH = heart failure hospitalization 
HR = hazard ratio 
ITT = intention to treat 
MACE = major adverse cardiovascular events 
MI = myocardial infarction 
PCI = percutaneous coronary intervention 
SGLT2i = sodium-glucose cotransporter-2 inhibitors 
VKA = vitamin K agonist  
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Introduction 
A year ago, we published a critical appraisal of some late-breaking trials at the 2018 
American College of Cardiology (ACC) Scientific Sessions (1). Rather than just repeat that 
for ACC 2019, we consider it more useful to take a broader perspective of key trials first 
presented and published in the past 12 months. Thus, in addition to ACC 2019, we cover 
trials from the annual 2018 Scientific Sessions of the Heart Rhythm Society, the European 
Society of Cardiology, the Transcatheter Cardiovascular Therapeutics, and the American 
Heart Association. 
We have selected 6 key recent trials (Central Illustration) for our constructive 
critical appraisal. These trials were chosen for a mix of reasons. They: 1) are of major clinical 
importance; 2) are within our sphere of expertise; 3) raise challenges in their interpretation; 
and 4) contain valuable insights for the methodology of clinical trials research. 
CABANA trial 
The CABANA (Catheter ABlation vs. ANtiarrhythmic Drug Therapy for Atrial 
Fibrillation: NCT00911508) trial (2) randomized 2,204 patients with atrial fibrillation to 
either catheter ablation or antiarrhythmic drug therapy. The primary composite endpoint was 
death, disabling stroke, serious bleeding, or cardiac arrest. Key secondary outcomes were all-
cause death and the composite of death and cardiovascular hospitalization (CVH). Over a 
median 4 years follow-up, findings for these outcomes using analysis by intention to treat 
(ITT) are summarized in the top part of Figure 1. Neither the primary endpoint nor all-cause 
death showed a significant treatment difference, though there were numerically fewer 
primary endpoints and deaths in the ablation arm. For the composite of death and CVH, ITT 
analysis did show a significant reduction in the ablation arm (p = 0.002). 
The main problem in interpreting CABANA is the high rates of treatment crossovers: 
9.2% of patients randomized to ablation did not receive it, whereas 27.5% of patients 
randomized to drug therapy did in fact receive ablation. This means that ITT analysis will 
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inevitably dilute away any true benefits of ablation. The widely accepted argument in favor 
of ITT analysis is that it achieves an unbiased comparison of the 2 therapeutic strategies as 
actually carried out. But the key flaw in the conduct of CABANA is the apparent lack of 
clinical equipoise: over one-quarter of investigators and their patients in the drug therapy arm 
received ablation, even though the whole purpose of the trial is that there is insufficient prior 
evidence that ablation is effective. In this context, the CABANA investigators have presented 
some alternative analyses (Figure 1). The precise methods undertaken are not fully 
explained, but our interpretation is as follows. Analysis by treatment received compares 
patients who actually received ablation with those who did not, regardless of which group 
they were randomized to. This approach shows highly significant differences in favor of 
ablation for the primary endpoint (hazard ratio [HR]: 0.67; p = 0.006) and all-cause death 
(HR: 0.60; p = 0.005). Per protocol analysis keeps patients in their randomized groups, but 
it removes from analysis those who crossed over. Only results for the primary endpoint are 
presented, with HR = 0.73; p = 0.046. 
Of course, all these alternative analyses may carry a substantial bias. The patients who 
crossover are not a random sample of all the patients in each randomized group, and such 
crossovers may carry a higher (or lower) risk of getting fatal and nonfatal events not directly 
related to the actual intervention received. Thus, such exploratory analyses, although 
supportive of the hypothesis that ablation is an effective treatment, cannot be considered 
definitive evidence. Overall, we believe that the evidence from CABANA is inconclusive.  
The underlying problem is that CABANA may well have been done too late in the 
development of catheter ablation for atrial fibrillation. In general, for any new procedure, 
there is first a learning curve, while the technical details and the interventionists’ (or 
surgeons’) skills are perfected, when it is too soon to undertake the pivotal randomized trial. 
There then follows a “window of opportunity” before the procedure gets widely accepted (3). 
In this case, that opportunity for unbiased randomized evidence appears to have been missed. 
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Perhaps this is an example of Buxton’s law: “it is always too early for rigorous evaluation, 
until unfortunately it’s suddenly too late.” 
In general, there remains controversy regarding the value of such “as treated” and 
“per protocol” analyses (4,5). To dismiss them as irrelevant is too harsh a stance, whereas to 
accept them as pivotal evidence is inappropriate. The key is to define exactly what one 
wishes to estimate (called the estimand) (6) and then to define the appropriate analysis 
strategy and any assumptions that it relies on. 
Given the CABANA trial’s problems, what additional evidence can be drawn on to 
clarify the merit (or not) of ablation therapy in atrial fibrillation? Of note is a large 
observational study using the OPTUM administrative database (7). They identified 135,688 
patients who would have been eligible for CABANA, of whom 6,907 patients underwent 
ablation. Mean follow-up after ablation was 1.5 years. Using a propensity score weighted 
analysis to adjust for potential confounders, they found patients receiving ablation had a 
lower risk of all-cause death (HR: 0.60; p < 0.001) and the composite of death, stroke, major 
bleed, and cardiac arrest (HR: 0.70; p < 0.001), the latter being the primary endpoint in 
CABANA (Figure 1). As in all such observational studies, one cannot rule out a selection 
bias whereby there are unmeasured confounders influencing who received ablation. 
Therefore, it is open to debate whether these apparent striking benefits of ablation are 
believable. 
CASTLE-AF (Catheter Ablation vs. Standard Conventional Treatment in Patients 
With Left Ventricular Dysfunction and Atrial Fibrillation: NCT00643188) (8) is another trial 
of catheter ablation versus medical therapy in 363 patients who had both atrial fibrillation and 
heart failure (see Figure 1). Over a median 3.15 years follow-up, treatments were compared 
using a modified ITT analysis; this excluded events during the run-in period and also nonfatal 
events during a 12-week “blanking period” after the baseline visit. The ablation group had 
fewer deaths (HR: 0.53; p = 0.009) and fewer primary endpoints, a composite of death and 
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heart failure hospitalization (HFH; HR: 0.62; p = 0.009). Again, the extent of treatment 
crossovers was substantial: 15.6% and 9.8%, respectively, in the ablation and medical therapy 
groups. But CASTLE-AF studied a different population (the subset of atrial fibrillation 
patients who also had heart failure), and therefore is not directly relevant to the question 
tackled by CABANA. 
The dilemma we face is that although no study provides definitive evidence that 
catheter ablation is an effective intervention in patients with atrial fibrillation, does the 
totality of evidence across a range of somewhat imperfect studies carry sufficient conviction? 
Recent guidelines (9) are cautious, providing catheter ablation with their weakest possible 
recommendation. The hope is that ongoing and future trials will resolve the issue. But will 
they, too, suffer from high crossover rates? 
ATTR-ACT trial 
The ATTR-ACT (Safety and Efficacy of Tafamidis in Patients With Transthyretin 
Cardiomyopathy: NCT01994889) trial (10) is a double-blind trial that randomized 441 
patients with transthyretin amyloid cardiomyopathy in a 2:1:2 ratio to 80 mg tafamidis, 20 
mg tafamidis, or matching placebo for 30 months. In the primary analysis, they hierarchically 
assessed all-cause mortality, followed by frequency of CVH using Finkelstein-Schoenfeld 
(11) and win ratio (12) methods. Before we interpret this relatively novel methodology and 
its results, let us describe the essential results for the key components of the primary analysis 
(Table 1). Throughout, the results compare both tafamidis doses combined (264 patients) 
with placebo (177 patients). 
For all-cause death over 30 months follow-up, the HR is 0.70 (95% confidence 
interval [CI]: 0.51 to 0.96; p = 0.026). For CVH, the investigators concentrate on comparing 
their overall frequency including repeat CVH within the same patient, with rates per year of 
0.48 and 0.70 in the tafamidis and placebo groups, respectively. One needs to allow for the 
nonindependence of repeat events (i.e., a few patients may contribute a lot of events), so 
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negative binomial analysis is the most informative (13), with a rate ratio 0.71 (95% CI: 0.54 
to 0.93; p = 0.0068). The alternative Poisson regression analysis, though pre-specified, falsely 
assumes independence of events, which makes the consequent CI narrower and the p value 
smaller than is appropriate. Had the investigators chosen to only analyze the time to first 
event (ignoring repeats) the results become less impressive: HR: 0.80 (95% CI: 0.62 to 1.03; 
p = 0.07). 
The Kaplan-Meier plots of mortality and first CVH (not shown) both show the effect 
of treatment, with their respective plots showing a divergence after around 18 months and 9 
months, respectively. Thus, an extended follow-up out to 30 months and inclusion of repeat 
CVHs in the primary analysis were crucial factors in demonstrating efficacy. 
In addition, the tafamidis group showed highly significant steady improvements over 
time for both functional capacity (6-min walk test) and quality of life (Kansas City 
Cardiomyopathy Questionnaire overall score). 
Now let us interpret the primary analysis that hierarchically assessed all-cause 
mortality, followed by frequency of CVH using the Finkelstein-Schoenfeld test (11) and the 
win ratio method (12). The win ratio is 1.70 (95% CI; 1.26 to 2.29; p = 0.0006). First, note 
that this p value is smaller than those separately obtained for mortality and CVHs. That is, 
combining the reductions in risk of death and CVH produces very strong evidence of a 
treatment effect and hence reinforces the value of this type of hierarchical analysis. But why 
not instead use a conventional composite endpoint of time to first CVH or death? Because 
this would have made inadequate use of the available data by: 1) ignoring repeat CVHs after 
the first one; and 2) ignoring any deaths that happen after a CVH. 
The win ratio method is relatively new, so many people do not understand it. Hence, 
Figure 2 is our attempt to explain how it works in ATTR-ACT. The win ratio analysis (14) is 
according to 2 stratification factors: transthyretin status (variant or wild type) and baseline 
New York Heart Association (NYHA) class (I/II or III). Thus, there are 4 patient strata: 
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variant type class I/II, variant type class III, wild type class I/II, and wild type class III 
comprising 58, 48, 242, and 93 patients, respectively. Then, within each stratum, every 
patient in the tafamidis group is compared with every patient in the placebo group: that is, 
there are 34 × 24 + 29 × 19 + 152 × 90 + 49 × 44 = 17,203 pairs of patients. For each pair, we 
determine whether the tafamidis patient “won” or “lost” compared to the placebo patient. 
There are 2 ways to decide this: 1) who died first (they are the “loser”); and then, 2) if neither 
died, who had the most CVHs (again they are the “loser”), both being assessed over their 
shared follow-up time (Figure 2). Adding up across strata, we get a total of 8,595 winners 
and 5,071 losers. Hence the win ratio is 8,595/5,071 = 1.70. The consequent 95% CI is 1.26 
to 2.29 with p = 0.0006 using the Finkelstein-Schoenfeld test. 
In conclusion, there is overwhelming evidence that patients on tafamidis had a better 
outcome than those on placebo. One outstanding issue is that the evidence is derived from 2 
different daily doses, 80 mg and 20 mg, studied in a 2:1 randomization ratio. At present, no 
results are given on how the 2 doses compare. We are informed that such results will be 
available soon, which is crucial because they will have an important bearing on future use of 
tafamidis. 
COAPT trial 
The COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous 
Therapy for Heart Failure Patients With Functional Mitral Regurgitation: NCT01626079) 
trial (15) randomized 614 patients with heart failure and moderate-to-severe mitral 
regurgitation to either mitral valve repair plus medical therapy (device group) or medical 
therapy alone (control group). Compliance was good: only 3% of the device group (N = 302 
patients) had no procedure attempted and 1% of the control group (N = 312 patients) 
underwent transcatheter mitral valve repair. The primary effectiveness endpoint was all HFHs 
over 24 months follow-up, and all-cause death was a key secondary endpoint (Figure 3). 
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The COAPT trial is one of the first published trials in cardiology to use a repeat 
events analysis for its primary endpoint: that is all HFHs (including repeats) contribute to the 
treatment comparison, not just the conventional time to first event (HFH or CV death). This 
approach has certain advantages: the total burden of relevant disease is better captured and 
also the statistical power of the trial is likely to be enhanced (16). However, the consequent 
statistical techniques are more complex and as yet there is no overall expert consensus 
regarding a universally accepted optimal method. 
But first let us look at the descriptive statistics. In the device and control groups, 
respectively, 92 and 151 patients had at least 1 HFH and the total number of HFHs (including 
repeats) were 160 and 283, respectively. These cumulative numbers of HFHs over time are 
shown in Figure 3A. The numbers of deaths over 2 years follow-up were 80 and 121 in the 
device and control groups, respectively (Figure 3B). These striking numerical differences 
require formal statistical analysis. For mortality that is straightforward, with a HR of 0.62 
(95% CI: 0.46 to 0.82; log-rank p < 0.001). For the primary endpoint, all HFHs, the issue is 
made more complicated by the fact that death is an informative censoring or competing risk. 
That is, patients who are more prone to have 1 or more HFHs are also at a higher risk of 
dying: the jargon term for this is joint frailty. Another issue is that some patients have 
multiple HFHs, and this lack of independence of such repeat events needs correcting for in 
the analysis. The precise methodology required (17) is too technical to describe here, but the 
end result is a joint-frailty adjusted HR for all HFHs of 0.53 (95% CI: 0.40 to 0.70; p < 
0.001). 
As a simpler plausibility check on such “black box” complexity, one can convert the 
total HFHs in the device and control groups, 160 and 283, respectively, into annualized rates 
of 35.8 and 67.9 per 100 patient-years. The consequent rate ratio is 0.53, a reassuringly 
identical result. It is useful to convert such estimates of relative treatment effect into absolute 
risk reductions. Accordingly, the authors report the number needed to treat to prevent 1 HFH: 
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3.1 (95% CI: 1.9 to 7.9), and also to prevent a death: 5.9 (95% CI: 3.9 to 11.7)—both over 2 
years of follow-up. 
The MITRA-FR (Multicentre Study of Percutaneous Mitral Valve Repair MitraClip 
Device in Patients With Severe Secondary Mitral Regurgitation: NCT01920698) trial (18) 
also compared mitral valve repair with medical therapy alone and came to very different 
conclusions. They randomized patients with severe secondary regurgitation to undergo 
percutaneous mitral valve repair plus medical therapy (device group, N = 152) or to receive 
medical therapy alone (control group, N = 152). The primary efficacy endpoint was a 
composite of death or unplanned HFH, (i.e., a conventional time-to-first-event analysis and 
follow-up is 12 months). The key results for both this primary efficacy endpoint and for all-
cause death are shown in Figure 4, with the corresponding results for COAPT shown 
alongside. 
MITRA-FR showed no significant difference between the device and control groups 
for the primary endpoint and for death (p = 0.53 and 0.66, respectively). Furthermore, the 
estimated HRs are numerically in favor of control (HR: 1.16 and 1.11, respectively). This is 
in sharp contrast to COAPT’s highly significant findings in favor of the device (HR: 0.57 and 
0.62, respectively; both p < 0.001). Interaction tests for between-trial heterogeneity of 
treatment effect for the primary endpoint and for all-cause death are both statistically 
significant (p = 0.007 and 0.039, respectively). 
There is no obvious single answer as to why the findings of these 2 trials differ so 
markedly (19,20). Points to consider are: 
1) Follow-up was only 1 year in MITRA-FR but 2 years in COAPT. COAPT showed a 
marked difference in HFH incidence at 1 year, whereas its difference in mortality at 1 
year, 19.3% versus 24.7%, is less striking, with a greater divergence in mortality out 
to 2 years, 29.1% versus 46.1%. Perhaps once MITRA-FR also achieves 2 years 
follow-up, the discrepancy between the trials may become less marked. 
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2) Did the trials differ in their use of medical therapy in both arms, both before patient 
entry and during follow-up? 
3) Were there differences in procedural performance? In all such trials of novel devices, 
there is a learning curve among interventionists, and was the level of operator 
experience adequately achieved in both trials? 
4) There are between-trial differences in patient eligibility criteria and also in the actual 
patterns of patient recruitment. Specifically, patients in MITRA-FR tended to have 
marked left ventricle dilation but a more modest degree of mitral regurgitation.  
The evident superiority of outcomes in the device arm of the COAPT trial is impressive. 
But like all such strategy trials of device versus control, the proportion of patients with the 
relevant condition (heart failure and secondary mitral regurgitation) who actually got 
randomized is relatively low. Thus, the key question for future therapeutic practice is can we 
successfully define an identifiable patient population for whom the use of transcatheter mitral 
valve repair is an optimal strategy? 
DECLARE trial 
The DECLARE-TIMI58 (Multicenter Trial to Evaluate the Effect of Dapagliflozin on the 
Incidence of Cardiovascular Events: NCT01730534) trial (21) randomized 17,160 patients 
with type 2 diabetes to dapagliflozin or placebo. Of these patients, 41% had established 
atherosclerotic CV disease, with the remainder having multiple risk factors. The coprimary 
endpoints were major adverse cardiovascular events (MACE: CV death, myocardial 
infarction [MI], stroke) and the composite of CV death or HFH. The pre-specified hierarchy 
of secondary endpoints was a renal composite and then all-cause death. MACE was also the 
primary safety outcome to comply with the Food and Drug Administration (FDA) 
requirement to undertake noninferiority testing of all new antidiabetic agents (22). 
Table 2 shows results for the primary, secondary, and other key outcomes over a median 
4.2 years follow-up. In order to preserve type I error and to accommodate potential interim 
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stopping of the trial, it was pre-declared that each coprimary endpoint had to achieve p < 
0.0231 to claim statistical significance. Only if both passed this hurdle was the sequence of 2 
secondary endpoints allowed to enter formal significance testing. 
In fact, of the 2 coprimaries, CV death and HFH revealed strong evidence of efficacy 
(HR: 0.83; 95% CI: 0.73 to 0.95; p = 0.005), whereas MACE did not (p = 0.17). Thus, no 
formal statistical testing was then performed on secondary endpoints. But the renal composite 
(the first secondary endpoint) had HR: 0.76 (95% CI: 0.67 to 0.87; p = 0.00004), an 
impressive result that is declared an exploratory finding, which formally does not constitute a 
claim of efficacy for renal benefits of dapagliflozin. 
We think this interpretation lacks common sense, and it could characterize a more general 
failing in the way secondary endpoints are handled in major trials. 
Here are a few suggestions: 
1) If a secondary endpoint exhibits overwhelming evidence of treatment superiority (as in 
this case), then this needs to be cautiously accepted in a trial’s conclusions. The FDA 
approval of empagliflozin for reducing CV death in the EMPA-REG OUTCOME (BI 
10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus 
Patients: NCT01131676) trial (23) is an example. 
2) The formal use of p values to aid decision-making is most important to regulators (e.g., 
FDA and European Medicines Agency) whose responsibility is to approve a drug (or not) 
for a specific indication. The medical journals have a different responsibility, the 
presentation of scientific evidence. Although type I error control is an important principle, 
it should not become an obsession suppressing important secondary findings. 
3) We do not agree with the current New England Journal of Medicine practice of not 
presenting p values for secondary endpoints if the primary endpoint(s) are not statistically 
significant. For instance, in Table 1, only the first 2 p values are reported in the paper by 
Maurer et al. (10). This feeds into the misinterpretation of p < 0.05 as an “accept or 
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reject” negative or positive philosophy of trial statistics, an issue one of us has critically 
appraised in 2 New England Journal of Medicine papers (24,25). 
4) Another widespread but suspect practice is to pre-define secondary endpoints in a pre-
defined hierarchy of statistical testing. Thus, trialists struggle as to what order to choose 
for their secondary endpoints, in effect having to “gaze into the crystal ball” as to which 
outcomes have the best chance of success while also bearing in mind their relative clinical 
importance. 
5) We recommend that this practice should stop. Instead we propose that in future trials we 
consider all pre-defined secondary endpoints on an equal footing while implementing a 
statistical correction for multiple testing (e.g., Bonferroni or Hochberg procedure). Thus, 
if one has 5 secondary endpoints and the primary endpoint is formally significant, then if 
one of them achieves p < 0.01, it should also be considered as a formally significant 
finding. 
We now turn our attention to how the DECLARE trial findings should be integrated into 
the overall evidence regarding the CV benefits of sodium-glucose cotransporter-2 inhibitors 
(SGLT2i). One way of accomplishing this is in a meta-analysis (26) combining findings from 
EMPA-REG (27), CANVAS (CANagliflozin cardioVascular Assessment Study: 
NCT01032629) (28), and DECLARE. We summarize and also extend their findings in 
Figure 5. 
For MACE (CV death, MI, and stroke) (Figure 5A), we see a consistency of benefit 
across trials in patients with pre-existing atherosclerotic disease: the overall HR is 0.86 (95% 
CI: 0.80 to 0.93; p = 0.0002). Even though this fell short of conventional significance in 
DECLARE, there is no evidence of heterogeneity across trials (interaction p = 0.63). 
However, in the 2 trials that did include patients with multiple risk factors only (CANVAS 
and DECLARE), there is no such signal of a benefit on MACE for such patients: the overall 
HR is 1.00 (95% CI: 0.87 to 1.16; p = 0.98. Note that the heterogeneity test comparing these 
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2 overall HRs is of marginal significance (interaction p = 0.07), so we need to exercise some 
restraint before presuming the whole MACE benefit story is solely confined to patients with 
pre-existing disease. 
For HFH and CV death, we see strong evidence of treatment efficacy across trials 
(Figure 5B), which applies equally well in patients with and without a history of heart 
failure: the HRs are 0.71 and 0.79, respectively, both p < 0.0001. This is the most 
consistently positive finding from these SGLT2i trials. Whether these findings for patients 
with heart failure also extrapolate to such patients without diabetes is currently being 
investigated in the EMPEROR-HF (EMPagliflozin outcomE tRial in Patients With chrOnic 
heaRt Failure: NCT03057951, NCT03057977) and Dapa-HF (Study to Evaluate the Effect of 
Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in 
Patients With Chronic Heart Failure: NCT03036124) trials. 
For CV death and all-cause death (Figure 5C and 5D), the striking reductions due to 
empagliflozin in the EMPA-REG trial have not been found in CANVAS and DECLARE. 
The tests for heterogeneity of effects across trials are significant (interaction p = 0.007 and p 
= 0.018, respectively, for CV death and all-cause death). As far as we understand, there is no 
obvious biological explanation for these differing effects on mortality. Faced with no back-up 
evidence, one is entitled to speculate that the surprisingly large magnitudes of observed 
effects with empagliflozin (HR: 0.62 and 0.68 for CV death and all-cause death, respectively) 
may be by chance an exaggeration of the truth, but it is hard to dispute the effects exists given 
their extreme significance (both p < 0.0001). 
REDUCE-IT trial 
The REDUCE-IT (Evaluation of the Effect of AMR101 on Cardiovascular Health and 
Mortality in Hypertriglyceridemic Patients With Cardiovascular Disease or at High Risk for 
Cardiovascular Disease: NCT01492361) trial (29) evaluated whether 2 g twice daily of 
icosapent ethyl, a purified ethyl ester of eicosapenteic acid (EPA) could reduce the risk of CV 
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events. A total of 8,179 patients, 71% with established CV disease and 29% with diabetes and 
other risk factors, who had been on a statin were randomized to EPA or placebo and followed 
for a median 4.9 years. The primary composite endpoint comprised CV death, MI, stroke, 
coronary revascularization, or unstable angina. 
Table 3 summarizes the key trial findings. There was a markedly reduced incidence 
of the primary endpoint (HR: 0.75; 95% CI: 0.68 to 0.83; p < 0.0001). Every component of 
the primary endpoint showed evidence of a significant effect, this being most marked for MI, 
coronary revascularization, and unstable angina. There were significantly fewer CV deaths on 
EPA (p = 0.03), but because non-CV deaths were almost identical in the 2 groups, the finding 
is more tenuous for all-cause death (p = 0.09). It is also worth noting that from Kaplan-Meier 
plots for the primary endpoint (and also for the key secondary endpoints of CV death, MI, 
and stroke), there is no evidence of a treatment effect in the first year of follow-up. 
These positive results in REDUCE-IT need to be set against the previous 
disappointing findings from other trials of omega-3 fatty acids. For instance, a meta-analysis 
of 10 such trials in 77,917 patients (30) gave for any major vascular event a HR of 0.97 (95% 
CI: 0.95 to 1.01). 
One statistical option when making sense of one positive trial in an otherwise 
negative field is to undertake Bayesian analyses. Thus, one expresses for the trial’s primary 
endpoint a plausible distribution of prior belief for the true HR and then uses Bayes’ theorem 
to combine such a prior belief distribution  with evidence from the trial to produce a posterior 
belief distribution (31). Because no one prior suits everyone, we present 3 scenarios: 
1. The pessimist’s prior. The pessimist does not perceive the specific omega-3 fatty 
acid used in REDUCE-IT as being any different from the rest. Hence, they use the 
meta-analysis estimate as the prior distribution and integrate it with the new data, as 
shown in Figure 6A. Because the prior data and pessimist’s belief distribution are so 
strongly negative, the evidence from REDUCE-IT only slightly shifts the belief, with 
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posterior belief having a median HR of 0.95 with a 95% credibility interval from 0.92 
to 0.98. But one should note that the prior meta-analysis and REDUCE-IT are in sharp 
disagreement: an interaction test comparing their respective HRs, 0.97 and 0.75, , has 
p < 0.001. Thus, one might argue that the pessimist’s prior reflects an overwhelming 
prejudice against all omega-3 fatty acids, which is clearly overruled by REDUCE-IT. 
2. The realist’s prior. The realist accepts the principle that the EPA in REDUCE-IT 
may be onto something better than previously studied omega-3 fatty acids, but 
believes equally that it might conceivably do harm. Thus, he chooses a prior 
distribution centered on no true effect (HR: 1) with a wider spread of uncertainty 
(Figure 6B). To be precise, we use a normal distribution for the prior of the log (HR), 
which has a positive tail out to 20% reduction in hazard with prior probability 0.025. 
In this scenario, the realist’s caution leads to a posterior belief having median HR of 
0.79 with a 95% credibility interval from 0.72 to 0.86. That is, the realist now accepts 
the positive finding in REDUCE-IT but is inclined to believe that the true effect of 
EPA is somewhat less than that observed. Note that if REDUCE-IT had been a much 
smaller trial, then the interpretation would be more cautious. For instance, if 
REDUCE-IT had been only one-quarter as big with the same observed HR of 0.75, 
then the posterior median belief would have been 0.85 with a 95% credibility interval 
of 0.75 to 0.99. That is, one needs a very large trial to convince people when previous 
evidence has been so negative. 
3. The optimist’s prior. The optimist asserts that the EPA and its high dose used in 
REDUCE-IT bears no relation to previous trials of other omega-3 fatty acids. One 
therefore has no prior insight into what the treatment effect might truly be. In such 
circumstances, one chooses a vague prior, in which case the evidence is its own 
posterior distribution automatically. Such optimism is implicit in any conventional 
(frequentist) presentation of results. That is, the published estimate, 95% CI, and p 
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value are compatible with a vague prior. This optimistic stance is encouraged by a 
Japanese trial of 1.8 g daily of icosapent ethyl (32), which showed a significant 19% 
reduction in coronary events, though that trial was not blinded.  
By its very nature, the use of Bayesian techniques to see whether a trial’s evidence is 
strong enough to overcome prior skepticism has no single right answer. But Bayesian 
methods are a quantitative tool that may help clarify the arguments. 
Another way of interpreting such a highly significant result in a unique trial is to argue 
how many replicate trials would have to achieve one-sided p < 0.025 to have the same 
strength of evidence as the observed significance for the primary endpoint, which for 
REDUCE-IT is p = 0.00000001. The answer is it would take 4 replicate trials, each with one-
sided p = 0.025, to approach the same level of proof beyond reasonable doubt that efficacy is 
established. 
Further insight into the efficacy of EPA is documented by the large reduction in total 
ischemic events in the REDUCE-IT trial (33). In addition to the 1,606 patients having a first 
primary event, there were a further 1,303 repeat events. There is an estimated 30% risk 
reduction in this total burden of ischemic events (95% CI: 22% to 38% reduction). 
But we do need to recognize the adverse event profile of EPA in the REDUCE-IT trial 
(Table 3). There are statistically significant increases in incidence of constipation (+1.8%), 
peripheral edema (+1.5%), and atrial fibrillation (+1.4%), the latter being of particular 
concern. These absolute risks need setting against the observed absolute benefits, which 
are -4.8% for the primary endpoint and -3.6% for the composite of CV death, MI, and stroke. 
Furthermore, the increase in peripheral edema is not accompanied by an increase in heart 
failure, and the increase in atrial fibrillation is offset by a significantly lower incidence of 
stroke.  
The European Medicines Agency has recently reviewed the totality of evidence for 
omega-3 fatty acid (34) and concluded, “the benefit-risk balance of omega-3 ethyl esters in 
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secondary prevention after myocardial infarction is not favorable.” The key question is, does 
the REDUCE-IT trial genuinely show that a high dose of icosapent ethyl has a much more 
favorable benefit-risk profile? 
AUGUSTUS trial 
The AUGUSTUS trial (An Open-label, 2 x 2 Factorial, Randomized Controlled, 
Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. 
Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or 
Percutaneous Coronary Intervention: NCT02415400) (35) was an open-label 2 × 2 factorial 
trial to evaluate the safety of apixiban versus a vitamin K agonist (VKA) and aspirin versus 
placebo in 4,614 patients with atrial fibrillation and acute coronary syndrome and/or 
percutaneous coronary intervention (PCI). All patients also received a P2Y12 inhibitor for 6 
months, and also aspirin on the actual day of acute coronary syndrome and/or PCI. The 
primary outcome through 6 months was major bleed or clinically relevant nonmajor (CRNM) 
bleeding using the International Society on Thrombosis and Haemostatis definitions. 
Secondary outcomes included major bleeding, death, rehospitalization, and ischemic events 
(i.e., MI, stroke, stent thrombosis, urgent revascularization).  
The nature of such a factorial trial (36) is that each patient is simultaneously 
randomized twice: to apixiban versus VKA and to aspirin versus placebo. Thus, there are 4 
treatment groups: apixiban + aspirin; apixiban + placebo; VKA + aspirin; VKA + placebo. 
However, the pre-defined analysis plan is to concentrate on results for each of the 2 treatment 
factors (apixiban vs. VKA and then aspirin vs. placebo) in all 4,614 randomized patients. 
This is accompanied by an interaction test examining whether any difference between 
apixiban and VKA depends on whether the patients received aspirin or placebo. Comparison 
of the 4 treatment groups is considered a secondary descriptive data display without formal 
statistical analysis. 
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Results for the primary and key secondary endpoints are shown in Table 4. For the 
primary endpoint, major and CRNM bleeding, there is strong evidence that apixiban is 
superior to VKA (HR: 0.69; 95% CI: 0.58 to 0.81; p < 0.0001). Also, aspirin is clearly 
inferior to placebo (HR: 1.90; 95% CI: 1.60 to 2.25; p < 0.0001). If one confines attention to 
major bleeds only, the same conclusions are evident. 
Results for hospitalization over 6 months reveal a significant reduction on apixiban 
compared with VKA (p = 0.002). There were also slightly more hospitalizations on aspirin 
compared with placebo (p = 0.12). There was an overall 3.3% mortality over 6 months with 
no evidence of treatment differences (data not shown). The composite of death and ischemic 
events had an overall 6.35% incidence over 6 months, again with no evidence of treatment 
differences (Table 4). For all these outcomes, the statistical tests of interaction were not 
statistically significant.  
We now display in Figure 7 the same outcomes broken down by the 4 randomized 
treatment groups: apixiban + aspirin; apixiban + placebo; VKA + aspirin; VKA + placebo. 
This provides reassuring evidence that the lowest incidence of both bleeding and 
hospitalizations is for patients on apixiban + placebo. A legitimate concern is that giving 
apixiban without aspirin might have increased the risk of ischemic events, but in fact, the 
incidence of the composite of death and ischemic events for apixiban + placebo is 
comparable to that for apixiban + aspirin. 
Given that the primary endpoint superiorities of apixiban over VKA and placebo over 
aspirin were very highly significant, one might question whether the trial should have been 
stopped earlier (37). One of us (S.J.P.) was on the trial’s Data Monitoring Committee that 
decided not to recommend early stopping. Like all trials of antithrombotic drugs, there is a 
tradeoff between treatment efficacy (prevention of ischemic events) and safety (an increased 
bleeding risk). Although AUGUSTUS was well powered to reach definitive findings on the 
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latter, the incidence of ischemic events was substantially lower. Therefore, early stopping of 
the trial would have inhibited the ability to reach clear conclusions on treatment efficacy. 
A network meta-analysis (38) has integrated the evidence from AUGUSTUS with 3 
other relevant trials. They concluded that a strategy based on non-VKA oral anticoagulants 
(such as apixiban) plus a P2Y12-inhibitor, but without aspirin, is the preferred regimen post-
PCI for patients who also have atrial fibrillation. 
Conclusion 
Each of the 6 clinical trials we have critiqued has important implications for future 
patient care. We have aimed to provide a balanced account of their key findings, how they fit 
into the context of previous knowledge, and each study’s strengths and weaknesses. 
Along the way, we have highlighted some methodological advances and challenges 
pertinent to trials research in general. These include:  
1. The problems of treatment crossovers and the cautious use of alternatives to ITT 
analysis.  
2. When to do a pivotal randomized trial of a new procedure requiring investigator 
skills. 
3. The use of new hierarchical methods (e.g., win ratio) for combining evidence from 
fatal and nonfatal events. 
4. The use of repeat events (not just time-to-first event) when comparing treatments in a 
chronic disease such as heart failure. 
5. Allowance for the competing risk of death when reporting the treatment effect on 
nonfatal events such as hospitalizations by use of joint-frailty models.  
6. How to interpret the overall evidence, when 2 related trials reach contrasting 
conclusions.  
7. The need for a better understanding of secondary endpoint findings, perhaps 
abandoning the current practice of hierarchical testing. 
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8. How to place a new trial in the context of prior related trials and appropriate use of 
meta-analyses. 
9. How to interpret a very positive trial in an otherwise negative field and the potential 
value of Bayesian methods. 
10. How to present and interpret the findings of a 2 × 2 factorial trial. 
Overall, we appreciate this opportunity to review some key recent randomized trials, and 
hope our insights are of value, for both their clinical relevance and their implications for 
future clinical trials research and its methodology. 
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Bullet points 
 This review is a constructive critical appraisal of key recent cardiology trial reports 
 The trials are ATTR-ACT, CABANA, COAPT, DECLARE, REDUCE-IT, and 
AUGUSTUS 
 For each study, we document and interpret the main findings 
 We pay particular attention to new findings, their research context and study 
limitations 
 Topical examples provide methodological insights pertinent to future clinical trials 
research. 
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Figure Legends 
Central Illustration: A Constructive Critical Appraisal of 6 Key Clinical Trials in 
Cardiology First Presented During May 2018 to March 2019. In time order of first 
presentation they are CABANA, ATTR-ACT, COAPT, DECLARE, REDUCE-IT, and 
AUGUSTUS. For each study, our aim is to document and interpret the main findings, paying 
attention to new findings, their research context, and study limitations. These topical 
examples also provide methodological insights pertinent to future clinical trials research. 
ACC = American College of Cardiology; ACS = acute coronary syndrome; AHA = American 
Heart Association; CV = cardiovascular; CVH = cardiovascular hospitalization; ESC = 
European Society for Cardiology; HFH = heart failure hospitalization; PCI = percutaneous 
coronary intervention; TCT = Transcatheter Cardiovascular Therapeutics; VKA = vitamin K 
agonist. 
Figure 1: Key Findings From the CABANA Trial, and Other Studies Comparing 
Catheter Ablation and Drug Therapy in Patients With Atrial Fibrillation. *The primary 
endpoint for CABANA (and OPTUM) is death, disabling stroke, serious bleeding, or cardiac 
arrest. + In the CABANA trial, the rate of crossovers in the ablation and drug therapy arms 
were 9.2% and 27.5%, respectively. In the CASTLE-AF trial, the corresponding crossover 
rates were 15.6% and 9.8%, respectively. Key findings from the CABANA trial (plus the 
OPTUM database and CASTLE-AF trial) comparing catheter ablation and drug therapy in 
patients with atrial fibrillation. ITT analysis did not show a significant treatment difference 
for either the primary endpoint or all-cause death, though there were numerically fewer 
primary endpoints and deaths in the ablation arm. For the composite of death and CVH, ITT 
analysis did show a significant reduction in the ablation arm (p = 0.001). Analysis by 
treatment received shows highly significant differences in favor of ablation for the primary 
endpoint (HR: 0.67; p = 0.006) and all-cause death (HR: 0.60; p = 0.005). Per protocol 
analysis showed a borderline significant difference for the primary endpoint. CI = confidence 
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interval; CV = cardiovascular; CVH = cardiovascular hospitalization; HR = hazard ratio; ITT 
= intention to treat; NR = not reported. 
Figure 2: Win Ratio Analysis of the Primary Hierarchical Endpoint of All-Cause Death 
and Frequency of CVH in the ATTR-ACT trial. Interpretation of win ratio = 1.7: if you 
compare any 2 patients in the same stratum, one on tafamidis and one on placebo, and they 
are not a tie (both alive with same number of CVHs) then the odds that the patient on 
tafamidis wins is 1.7. For people who prefer probabilities, then the probability that the patient 
on tafamidis wins is 1.7/(1.7 + 1) = 0.63. Win ratio analysis of the primary hierarchical 
endpoint of: (A) all-cause death; and (B) frequency of CVH in the ATTR-ACT trial. Patients 
are in 4 strata based on transthyretin status (variant or wild type) and NYHA class (I/II or III). 
Within each stratum, every patient in the tafamidis group is compared with every patient in 
the placebo group. For each pair it is determined over their shared follow-up time, first 
whether the patient on tafamidis “wins” or “loses” on death and then, if “tied” on death, 
whether the patient on tafamidis “wins” or “loses” on the number of CVH. There were 8,595 
winners and 5,071 losers, giving a win ratio of 1.70 (95% CI: 1.26 to 2.29; p = 0.0006). CVH 
= cardiovascular hospitalization; CI = confidence interval; NYHA = New York Heart 
Association. 
Figure 3: Cumulative Incidence of HFHs (Including Repeats) and Death From Any 
Cause in the COAPT Trial. Cumulative incidence of (A) the primary effectiveness endpoint 
(HFHs, including repeats over 24 months) and (B) death from any cause in the COAPT trial. 
The COAPT trial randomized 614 patients with heart failure and moderate-to-severe mitral 
regurgitation to either mitral valve repair plus medical therapy (device group) or medical 
therapy alone (control group). The joint-frailty adjusted HR for the primary effectiveness 
endpoint is 0.53 (95% CI: 0.40 to 0.70; p < 0.001). The HR for all-cause mortality is 0.62 
(95% CI: 0.46 to 0.82; p < 0.001). Reprinted, with permission, from Stone et al. (15). HFH = 
heart failure hospitalization. Other abbreviations as in Figure 1. 
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Figure 4: Comparison of the COAPT and MITRA-FR Trials for the Composite of 
Death and HFH and All-Cause Death at 1 Year. Both trials randomized patients to 
undergo percutaneous mitral valve repair plus medical therapy (device group) or to medical 
therapy alone (control group). MITRA-FR showed no significant difference between the 
device and control groups for the primary endpoint and for death (p = 0.53 and 0.66, 
respectively), and furthermore, the estimated HRs are numerically in favor of control (HR: 
1.16 and 1.11, respectively). This is in sharp contrast to COAPTs highly significant findings 
in favor of the device (HR: 0.57 and 0.62, respectively, both p < 0.001). Interaction tests for 
between-trial heterogeneity of treatment effect for the primary endpoint and for all-cause 
death are both statistically significant (p = 0.007 and 0.039, respectively). Abbreviations as in 
Figures 1 and 3. 
Figure 5: Fixed-Effect Meta-Analysis of 3 SGLT2i Trials for MACE, HFH, CV Death, 
and All-Cause Death. Fixed effect meta-analysis of EMPA-REG OUTCOME, CANVAS 
Program and DECLARE SGLT2i trials for (A) MACE, (B) HFH, (C) CV death, and (D) all-
cause death. For MACE, we see a consistent benefit across trials for patients with pre-
existing atherosclerotic disease (HR: 0.86; 95% CI 0.80 to 0.93; p = 0.0002) but no evidence 
of any benefit for patients with multiple risk factors only. For HFH and CV death, we see 
strong evidence of treatment efficacy across trials, which applies equally well in patients with 
and without a history of heart failure (HR: 0.71 and 0.79 respectively, both p < 0.0001). For 
CV death and all-cause death, the striking reductions in the EMPA-REG trial have not been 
found in CANVAS and DECLARE. The tests for heterogeneity of effects across trials are 
significant (interaction p = 0.007 and p = 0.018, respectively, for CV death and all-cause 
death). MACE = major adverse cardiovascular events. Other abbreviations as in Figures 1 
and 3.  
Figure 6: Alternative Bayesian Analyses and Interpretations of the REDUCE-IT Trial 
Results for its Primary Endpoint. First (A), using a pessimist’s prior based on a meta-
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analysis of previous trials of omega-3 fatty acids, the posterior belief remains cautious (HR: 
0.95; 95% CI: 0.92 to 0.98). Second (B), using a realist’s prior, which cautiously accepts that 
some modest benefit (or harm) of eicosapenteic acid is possible, the evidence from 
REDUCE-IT is very influential producing a posterior belief distribution centered on a 21% 
risk reduction (HR: 0.79; 95% CI: 0.72 to 0.86). Third, using an optimist’s vague prior, 
implying previous studies are irrelevant, the posterior belief is the same as the REDUCE-IT 
evidence, as shown by the red distribution curves in (A) and (B) (HR: 0.75; 95% CI: 0.68 to 
0.83). Abbreviations as in Figure 1. 
Figure 7: Main Findings from the AUGUSTUS Trial for the 4 Randomized Treatment 
Options. Main findings from the AUGUSTUS trial, an open-label 2 × 2 factorial trial 
evaluating the safety of: i) apixiban versus vitamin K agonist (VKA); and ii) aspirin versus 
placebo in patients with atrial fibrillation and acute coronary syndrome (ACS) and/or 
percutaneous coronary intervention. The percentage with an event is shown for the primary 
endpoint (major or CRNM bleed) and key secondary endpoints for each of the 4 randomized 
treatment combinations. The number of patients on each of the 4 treatment options was 1,145 
apixiban + aspirin (green), 1,143 apixiban + placebo (gold), 1,123 VKA + aspirin (red), and 
1,126 VKA + placebo (blue). This provides reassuring evidence that the lowest incidence of 
both bleeding and hospitalizations is for patients on apixiban + placebo. A legitimate concern 
is that giving apixiban without aspirin might have increased the risk of ischemic events, but 
in fact, the incidence of the composite of death and ischemic events for apixiban + placebo is 
comparable to that for apixiban + aspirin. *Ischemic events are: myocardial infarction, stroke, 
stent thrombosis, urgent revascularization.   
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Table 1 Findings of the ATTR-ACT Trial for All-Cause Mortality and CVH 
 
 
Tafamidis 
(N = 264) 
Placebo 
(N = 177) 
HR (95% CI) 
(Risk Ratio for CVH 
rate) 
p Value 
Deaths* 39 (14.8%) 38 (21.5%) 0.70 (0.51–0.96) 0.026 
Number with ≥1 CVH  138 (52.3%) 107 (60.5%) 0.80 (0.62–1.03) 0.078 
Number of CVHs (including 
repeats) 
267 231   
CVH rate per year 0.48 0.70 0.71† (0.54–0.93) 0.0068 
* Heart transplant and implantation of a cardiac mechanical assist device were treated as 
deaths for this published analysis (and also for the win ratio analysis in Figure 2). If they 
were not treated as deaths, the HR for death becomes 0.67 with p = 0.018.  
† This risk ratio is from a negative binomial model that allows for the nonindependence of 
repeat hospitalizations within a patient 
CI = confidence interval; CVH = cardiovascular hospitalization; HR = hazard ratio.  
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Table 2: Key Efficacy Outcomes (and Their Components) in the DECLARE trial 
 
Outcome 
Dapagliflozin Placebo 
HR 
(95% CI) 
p Value 
(N = 8,582) (N = 8,578) 
n 
rate/1,000 
patient-yr n 
rate/1000 
patient-yr 
CV death or HFH* 417  12.2   496  14.7   
0.83 (0.73-
0.95) 
0.005 
MACE* 756  22.6   803  24.2   
0.93 (0.84-
1.03) 
0.17 
Renal composite† 370  10.8   480  14.1   
0.76 (0.67-
0.87) 
0.000038 
Death from any cause‡ 529  15.1   570  16.4   
0.93 (0.82-
1.04) 
0.23 
HFH 212  6.2   286  8.5   
0.73 (0.61-
0.88) 
0.00076 
Myocardial infarction   393  11.7   441  13.2   
0.89 (0.77-
1.01) 
0.092 
Ischemic stroke   235  6.9   231  6.8   
1.01 (0.84-
1.21) 
0.91 
CV death   245  7.0   249  7.1   
0.98 (0.82-
1.17) 
0.82 
Non-CV death 211  6.0   238  6.8   
0.88 (0.73-
1.06) 
0.18 
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≥40% decrease in eGFR 
to <60 ml/min/1.73m2, 
ESRD or renal death 
127  3.7   238  7.0   
0.53 (0.43-
0.66) 
<0.000001 
* Coprimary endpoints. † Renal composite (the first secondary endpoint) comprises ≥40% decrease in 
eGFR to <60 ml/min/1.73 m2, ESRD, or death from renal or CV cause. ‡ The second secondary 
endpoint. 
    CV = cardiovascular; eGFR = estimated glomerular filtration rate; ESRD = end-stage renal disease; 
HFH = heart failure hospitalization; MACE = major adverse cardiovascular events. Other abbreviations 
as in Table 1. 
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Table 3: Key Results From the REDUCE-IT Trial: Primary Endpoint, its 
Components, Mortality, and Adverse Events 
Outcome 
Icosapent 
Ethyl Placebo HR (95% CI) p Value 
(N = 4,089) (N = 4,090) 
Primary composite 17.2% 22.0% 0.75 (0.68–0.83) <0.001 
Myocardial infarction 6.1% 8.7% 0.69 (0.58–0.81) <0.001 
Urgent revascularization 5.3% 7.8% 0.65 (0.55–0.78) <0.001 
Unstable angina 2.6% 3.8% 0.68 (0.53–0.87) 0.002 
Stroke 2.4% 3.3% 0.72 (0.55–0.93) 0.01 
Cardiovascular death 4.3% 5.2% 0.80 (0.66–0.98) 0.03 
All-cause death 6.7% 7.6% 0.87 (0.74–1.02) 0.09 
     
Constipation* 5.4% 3.6% 
 
<0.001 
Peripheral edema* 6.5% 5.0% 
 
0.002 
Atrial fibrillation* 5.3% 3.9%   0.003 
Hospitalized atrial 
fibrillation 3.1% 2.1%  0.004 
* These adverse events were not adjudicated   
Abbreviations as in Table 1. 
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Table 4 Results for the AUGUSTUS Trial’s Primary and Key Secondary Endpoints Comparing Apixiban Versus VKA and Aspirin 
Versus Placebo Over 6 Months Follow-Up 
 
 
Apixiban 
(N = 2,306) 
VKA 
(N = 2,308) 
HR (95% CI) p Value  
Aspirin 
(N = 2,307) 
Placebo 
(N = 2,307) 
HR (95% CI) p Value 
Interaction 
p* 
Major + CRNM bleed 
(primary endpoint) 
10.5% 14.7% 0.69 (0.58–0.81) <0.0001  16.1% 9.0% 1.90 (1.60–2.25) <0.0001 0.716 
Major bleed 3.0% 4.6% 0.64 (0.47–0.86) 0.005  4.7% 2.9% 1.70 (1.25–2.32) 0.001 0.197 
Hospitalization 22.5% 26.3% 0.83 (0.74–0.93) 0.002  25.4% 23.4% 1.10 (0.98–1.24) 0.123 0.269 
Death or ischemic 
event
† 
6.2% 6.5% 0.94 (0.75–1.18) 0.592  5.9% 6.8% 0.88 (0.70–1.11) 0.251 0.325 
* The interaction test assesses whether the treatment difference between apixiban and VKA depends on whether the patient received aspirin or 
placebo. 
† Ischemic events are: myocardial infarction, stroke, stent thrombosis, urgent revascularization. 
CRNM = clinically relevant nonmajor; VKA = vitamin K agonist. Other abbreviations as in Table 1. 
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Figure 1: Key findings from the CABANA trial, and other studies comparing catheter ablation and 
drug therapy in patients with atrial fibrillation 
 
 
* The primary endpoint for CABANA (and OPTUM) is death, disabling stroke, serious bleeding or 
cardiac arrest. + In the CABANA trial the rate of crossovers in the ablation and drug therapy arms 
were 9.2% and 27.5% respectively. In the CASTLE-AF trial the corresponding crossover rates were 
15.6% and 9.8% respectively.  NR=not reported. 
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Figure 2 Win ratio analysis of the primary hierarchical endpoint of a) all-cause death and b) 
frequency of cardiovascular hospitalizations (CVH) in the ATTR-ACT trial. Patients are in 4 strata 
based on TTR status (variant or wild type) and NYHA class (I/II or III). 
 
 
 
Interpretation of win ratio 1.7: if you compare any two patients in the same stratum, one on 
tafamidis and one on placebo, and they are not a tie (both alive with same number of CVHs) then 
the odds that the tafamidis patient wins is 1.7. For people who prefer probabilities, then the 
probability that the tafamidis patient wins is 1.7/(1.7+1) = 0.63.  
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Figure 3: Cumulative incidence of A) heart failure hospitalizations (including repeats) and B) death 
from any cause in the COAPT trial 
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Figure 4: A comparison of the COAPT and MITRA-FR trials for A) composite of death and heart failure 
hospitalization and B) all-cause death. 
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Figure 5: Fixed effect meta-analysis of three SGLT2i trials for A) MACE B) heart failure hospitalization, 
C) cardiovascular death and D) all cause death. 
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Figure 6: Alternative Bayesian analyses and interpretations of the REDUCE-IT trial results for its 
primary endpoint* 
 
* A: using a pessimist’s prior based on a meta-analysis of previous trials of omega 3 fatty acids, the 
posterior belief remains cautious 
B: using a realist’s prior which cautiously accepts that some modest benefit (or harm) of EPA is 
possible, the evidence from REDUCE-IT is very influential producing a posterior belief distribution 
centred on a 21% risk reduction 
C: using an optimist’s vague prior, implying previous negative studies are irrelevant, the posterior 
belief is the same as the REDUCE-IT evidence as shown by the red distribution curves in A and B. 
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Figure 7 Main findings from the AUGUSTUS trial for the four randomized treatment options: 
apixiban+aspirin (green), apixiban+placebo (gold), VKA+aspirin (red), VKA+placebo (blue). Number of 
patients were 1145, 1143, 1123 and 1126 respectively.  
 
 
*  Ischemic events are: MI, stroke, stent thrombosis, urgent revascularization 
 
